Australian cancer treatment company,  Prima Biomed,  has announced its CEO Martin Rogers, will step down from August 31, but will remain on the board as a non-executive director. Mr Rogers has been in the position for four and a half years.


Matthew Lehman, the Company’s Chief Operating Officer, will assume the CEO role and will join the Prima board of directors. He will relocate from Germany to the San Francisco Bay Area, where Prima plans to concentrate its longer-term operational expansion.


Prima Chairman Lucy Turnbull said Mr Rogers had  consolidated Prima’s research activities to focus on development of CVac, brought together a strong management team and board of directors, and overseen the globalization of Prima’s development activities with key operations in the USA and Germany.


The company also announced that Dr. Neil Frazer has stepped down from his position as an executive director on the board, but will continue his senior management role as Chief Medical Officer.


In other changes to senior management, Dr. Sharron Gargosky has been promoted to Chief Technical Officer. Dr. Gargosky, based on the West Coast of the US, is charged with leading the scientific and technical development of CVac globally. Marc Voigt has been promoted to General Manager of the German subsidiary and Chief Business Officer of the Company. Mr. Voigt will be globally responsible for coordinating investor relations and driving business development.